Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2006-05-18 09:03:34 UTC |
---|
Update Date | 2022-03-07 02:49:11 UTC |
---|
HMDB ID | HMDB0001938 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Lisinopril |
---|
Description | One of the Angiotensin-converting enzyme inhibitors (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure. -- Pubchem; Lisinopril is a drug of the angiotensin converting enzyme (ACE) inhibitor class that is primarily used in treatment of hypertension, congestive heart failure and heart attacks. Historically, lisinopril was the third ACE inhibitor, after captopril and enalapril that was introduced into therapy in early 1990s. Lisinopril has a number of properties that distinguish it from other ACE inhibitors: it is hydrophilic, has long half life and tissue penetration and is not metabolized by the liver. -- Wikipedia ; Lisinopril is solely excreted in urine in the unchanged form. Elimination of the drug depends on glomerular filtration and tubular excretion. Rate of lisinopril elimination decreases with old age and kidney or heart failure. There is a relation between creatinine and lisinopril clearance. With prolonged therapy dose reduction can be necessary to avoid accumulation. -- Wikipedia . |
---|
Structure | NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline | ChEBI | [N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline | ChEBI | Lisinopril anhydrous | ChEBI | Zestril | Kegg | Acerbon | HMDB | Acercomp | HMDB | Alapril | HMDB | Carace | HMDB | Cipral | HMDB | Cipril | HMDB | Coric | HMDB | Inhibril | HMDB | Inopril | HMDB | Linopril | HMDB | Linvas | HMDB | Lipril | HMDB | Lisinal | HMDB | Lisinoprilum | HMDB | Lisipril | HMDB | Lisoril | HMDB | Lispril | HMDB | Loril | HMDB | LPR | HMDB | Lysinopril | HMDB | Noperten | HMDB | Novatec | HMDB | Presiten | HMDB | Prinil | HMDB | Prinivil | HMDB | Sinopril | HMDB | Sinopryl | HMDB | Tensopril | HMDB | Tensyn | HMDB | Tersif | HMDB | Vivatec | HMDB | Lisinopril maleate (1:1) | HMDB | Lisinopril sulfate (1:2) | HMDB |
|
---|
Chemical Formula | C21H31N3O5 |
---|
Average Molecular Weight | 405.4879 |
---|
Monoisotopic Molecular Weight | 405.226371117 |
---|
IUPAC Name | (2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid |
---|
Traditional Name | lisinopril |
---|
CAS Registry Number | 83915-83-7 |
---|
SMILES | NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O |
---|
InChI Identifier | InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1 |
---|
InChI Key | RLAWWYSOJDYHDC-BZSNNMDCSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Dipeptides |
---|
Alternative Parents | |
---|
Substituents | - Alpha-dipeptide
- N-acyl-alpha-amino acid
- Proline or derivatives
- N-acyl-alpha amino acid or derivatives
- N-acyl-l-alpha-amino acid
- Alpha-amino acid amide
- Alpha-amino acid
- Alpha-amino acid or derivatives
- L-alpha-amino acid
- N-acylpyrrolidine
- Pyrrolidine carboxylic acid
- Pyrrolidine carboxylic acid or derivatives
- Aralkylamine
- Benzenoid
- Monocyclic benzene moiety
- Dicarboxylic acid or derivatives
- Tertiary carboxylic acid amide
- Pyrrolidine
- Amino acid or derivatives
- Carboxamide group
- Amino acid
- Organoheterocyclic compound
- Secondary amine
- Azacycle
- Carboxylic acid
- Secondary aliphatic amine
- Hydrocarbon derivative
- Primary aliphatic amine
- Organic oxide
- Organic nitrogen compound
- Organonitrogen compound
- Carbonyl group
- Organooxygen compound
- Primary amine
- Amine
- Organic oxygen compound
- Organopnictogen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 97 mg/mL | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times UnderivatizedChromatographic Method | Retention Time | Reference |
---|
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.45 minutes | 32390414 | Predicted by Siyang on May 30, 2022 | 10.4516 minutes | 33406817 | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 6.51 minutes | 32390414 | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 388.0 seconds | 40023050 | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 758.6 seconds | 40023050 | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 188.8 seconds | 40023050 | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 133.9 seconds | 40023050 | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 177.3 seconds | 40023050 | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 95.7 seconds | 40023050 | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 305.5 seconds | 40023050 | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 338.1 seconds | 40023050 | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 1004.6 seconds | 40023050 | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 708.3 seconds | 40023050 | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 314.1 seconds | 40023050 | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 846.2 seconds | 40023050 | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 203.9 seconds | 40023050 | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 258.5 seconds | 40023050 | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 645.3 seconds | 40023050 | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 519.8 seconds | 40023050 | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 228.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Lisinopril,1TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O | 3337.1 | Semi standard non polar | 33892256 | Lisinopril,1TMS,isomer #2 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N[C@@H](CCC1=CC=CC=C1)C(=O)O | 3396.6 | Semi standard non polar | 33892256 | Lisinopril,1TMS,isomer #3 | C[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O | 3549.8 | Semi standard non polar | 33892256 | Lisinopril,1TMS,isomer #4 | C[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O | 3366.3 | Semi standard non polar | 33892256 | Lisinopril,2TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C | 3300.6 | Semi standard non polar | 33892256 | Lisinopril,2TMS,isomer #2 | C[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 3407.0 | Semi standard non polar | 33892256 | Lisinopril,2TMS,isomer #3 | C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C | 3256.6 | Semi standard non polar | 33892256 | Lisinopril,2TMS,isomer #4 | C[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C | 3443.5 | Semi standard non polar | 33892256 | Lisinopril,2TMS,isomer #5 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C | 3264.7 | Semi standard non polar | 33892256 | Lisinopril,2TMS,isomer #6 | C[Si](C)(C)N(CCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C | 3565.4 | Semi standard non polar | 33892256 | Lisinopril,2TMS,isomer #7 | C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C | 3422.6 | Semi standard non polar | 33892256 | Lisinopril,3TMS,isomer #1 | C[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C | 3379.5 | Semi standard non polar | 33892256 | Lisinopril,3TMS,isomer #1 | C[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C | 3347.0 | Standard non polar | 33892256 | Lisinopril,3TMS,isomer #1 | C[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C | 4153.2 | Standard polar | 33892256 | Lisinopril,3TMS,isomer #2 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 3233.8 | Semi standard non polar | 33892256 | Lisinopril,3TMS,isomer #2 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 3215.6 | Standard non polar | 33892256 | Lisinopril,3TMS,isomer #2 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 4580.6 | Standard polar | 33892256 | Lisinopril,3TMS,isomer #3 | C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 3483.7 | Semi standard non polar | 33892256 | Lisinopril,3TMS,isomer #3 | C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 3406.4 | Standard non polar | 33892256 | Lisinopril,3TMS,isomer #3 | C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 4353.1 | Standard polar | 33892256 | Lisinopril,3TMS,isomer #4 | C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 3338.3 | Semi standard non polar | 33892256 | Lisinopril,3TMS,isomer #4 | C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 3338.2 | Standard non polar | 33892256 | Lisinopril,3TMS,isomer #4 | C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 4304.5 | Standard polar | 33892256 | Lisinopril,3TMS,isomer #5 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N[C@@H](CCC1=CC=CC=C1)C(=O)O | 3525.3 | Semi standard non polar | 33892256 | Lisinopril,3TMS,isomer #5 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N[C@@H](CCC1=CC=CC=C1)C(=O)O | 3406.0 | Standard non polar | 33892256 | Lisinopril,3TMS,isomer #5 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N[C@@H](CCC1=CC=CC=C1)C(=O)O | 4359.2 | Standard polar | 33892256 | Lisinopril,3TMS,isomer #6 | C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C | 3350.6 | Semi standard non polar | 33892256 | Lisinopril,3TMS,isomer #6 | C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C | 3364.6 | Standard non polar | 33892256 | Lisinopril,3TMS,isomer #6 | C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C | 4274.6 | Standard polar | 33892256 | Lisinopril,3TMS,isomer #7 | C[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 3551.2 | Semi standard non polar | 33892256 | Lisinopril,3TMS,isomer #7 | C[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 3429.7 | Standard non polar | 33892256 | Lisinopril,3TMS,isomer #7 | C[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 4496.8 | Standard polar | 33892256 | Lisinopril,4TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C | 3490.5 | Semi standard non polar | 33892256 | Lisinopril,4TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C | 3422.5 | Standard non polar | 33892256 | Lisinopril,4TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C | 4012.4 | Standard polar | 33892256 | Lisinopril,4TMS,isomer #2 | C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 3335.2 | Semi standard non polar | 33892256 | Lisinopril,4TMS,isomer #2 | C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 3356.1 | Standard non polar | 33892256 | Lisinopril,4TMS,isomer #2 | C[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 3936.4 | Standard polar | 33892256 | Lisinopril,4TMS,isomer #3 | C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C | 3527.6 | Semi standard non polar | 33892256 | Lisinopril,4TMS,isomer #3 | C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C | 3427.9 | Standard non polar | 33892256 | Lisinopril,4TMS,isomer #3 | C[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C | 4155.9 | Standard polar | 33892256 | Lisinopril,4TMS,isomer #4 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C | 3536.1 | Semi standard non polar | 33892256 | Lisinopril,4TMS,isomer #4 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C | 3442.7 | Standard non polar | 33892256 | Lisinopril,4TMS,isomer #4 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C | 4125.9 | Standard polar | 33892256 | Lisinopril,5TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 3573.3 | Semi standard non polar | 33892256 | Lisinopril,5TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 3438.8 | Standard non polar | 33892256 | Lisinopril,5TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C)[Si](C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C)[Si](C)(C)C | 3837.2 | Standard polar | 33892256 | Lisinopril,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O | 3605.0 | Semi standard non polar | 33892256 | Lisinopril,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N[C@@H](CCC1=CC=CC=C1)C(=O)O | 3661.7 | Semi standard non polar | 33892256 | Lisinopril,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O | 3746.9 | Semi standard non polar | 33892256 | Lisinopril,1TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O | 3629.7 | Semi standard non polar | 33892256 | Lisinopril,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 3807.7 | Semi standard non polar | 33892256 | Lisinopril,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 3875.8 | Semi standard non polar | 33892256 | Lisinopril,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C(C)(C)C | 3820.6 | Semi standard non polar | 33892256 | Lisinopril,2TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 3916.1 | Semi standard non polar | 33892256 | Lisinopril,2TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C | 3840.3 | Semi standard non polar | 33892256 | Lisinopril,2TBDMS,isomer #6 | CC(C)(C)[Si](C)(C)N(CCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C(C)(C)C | 4034.3 | Semi standard non polar | 33892256 | Lisinopril,2TBDMS,isomer #7 | CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C | 3934.9 | Semi standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 4052.6 | Semi standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 3868.2 | Standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NCCCC[C@H](N[C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 4307.2 | Standard polar | 33892256 | Lisinopril,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4040.9 | Semi standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3741.1 | Standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4587.7 | Standard polar | 33892256 | Lisinopril,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 4194.0 | Semi standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 3921.6 | Standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 4442.0 | Standard polar | 33892256 | Lisinopril,3TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4114.3 | Semi standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3852.7 | Standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4426.1 | Standard polar | 33892256 | Lisinopril,3TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N[C@@H](CCC1=CC=CC=C1)C(=O)O | 4219.0 | Semi standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N[C@@H](CCC1=CC=CC=C1)C(=O)O | 3909.6 | Standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #5 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N[C@@H](CCC1=CC=CC=C1)C(=O)O | 4439.9 | Standard polar | 33892256 | Lisinopril,3TBDMS,isomer #6 | CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C | 4127.2 | Semi standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #6 | CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C | 3859.9 | Standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #6 | CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C | 4394.1 | Standard polar | 33892256 | Lisinopril,3TBDMS,isomer #7 | CC(C)(C)[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 4272.1 | Semi standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #7 | CC(C)(C)[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 3926.2 | Standard non polar | 33892256 | Lisinopril,3TBDMS,isomer #7 | CC(C)(C)[Si](C)(C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O | 4544.9 | Standard polar | 33892256 | Lisinopril,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 4380.4 | Semi standard non polar | 33892256 | Lisinopril,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 4055.4 | Standard non polar | 33892256 | Lisinopril,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 4194.3 | Standard polar | 33892256 | Lisinopril,4TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4302.1 | Semi standard non polar | 33892256 | Lisinopril,4TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3992.5 | Standard non polar | 33892256 | Lisinopril,4TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4174.1 | Standard polar | 33892256 | Lisinopril,4TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C(C)(C)C | 4461.9 | Semi standard non polar | 33892256 | Lisinopril,4TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C(C)(C)C | 4061.7 | Standard non polar | 33892256 | Lisinopril,4TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)N1CCC[C@H]1C(=O)O)[Si](C)(C)C(C)(C)C | 4305.3 | Standard polar | 33892256 | Lisinopril,4TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C | 4459.3 | Semi standard non polar | 33892256 | Lisinopril,4TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C | 4051.3 | Standard non polar | 33892256 | Lisinopril,4TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N([C@@H](CCC1=CC=CC=C1)C(=O)O)[Si](C)(C)C(C)(C)C | 4273.0 | Standard polar | 33892256 |
|
---|
General References | - Corradi HR, Schwager SL, Nchinda AT, Sturrock ED, Acharya KR: Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J Mol Biol. 2006 Mar 31;357(3):964-74. Epub 2006 Jan 31. [PubMed:16476442 ]
- Alves MF, Araujo MC, Juliano MA, Oliveira EM, Krieger JE, Casarini DE, Juliano L, Carmona AK: A continuous fluorescent assay for the determination of plasma and tissue angiotensin I-converting enzyme activity. Braz J Med Biol Res. 2005 Jun;38(6):861-8. Epub 2005 Jun 1. [PubMed:15933779 ]
- Tashtoush BM, Alali FQ, Najib NM: Liquid chromatographic-mass spectrometric method for quantitative determination of lisinopril in human plasma. Pharmazie. 2004 Jan;59(1):21-4. [PubMed:14964416 ]
- Swaisland AJ: The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. J Hum Hypertens. 1991 Dec;5 Suppl 2:69-71. [PubMed:1665181 ]
- Lanzillo JJ, Stevens J, Dasarathy Y, Yotsumoto H, Fanburg BL: Angiotensin-converting enzyme from human tissues. Physicochemical, catalytic, and immunological properties. J Biol Chem. 1985 Dec 5;260(28):14938-44. [PubMed:2999099 ]
- Huang J, Xu Y, Liu F, Gao S, Guo Q: Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of lisinopril in human plasma. Rapid Commun Mass Spectrom. 2006;20(2):248-52. [PubMed:16345121 ]
- Sudoh T, Fujimura A, Shiga T, Tateishi T, Sunaga K, Ohashi K, Ebihara A: Influence of lisinopril on urinary electrolytes excretion after furosemide in healthy subjects. J Clin Pharmacol. 1993 Jul;33(7):640-3. [PubMed:8396158 ]
- Ranieri G, Andriani A, Lamontanara G, De Cesaris R: Effects of lisinopril and amlodipine on microalbuminuria and renal function in patients with hypertension. Clin Pharmacol Ther. 1994 Sep;56(3):323-30. [PubMed:7924128 ]
- Haenni A, Reneland R, Andersson PE, Lind L, Lithell H: Skeletal muscle magnesium content is correlated with plasma glucose concentration in patients with essential hypertension treated with lisinopril or bendrofluazide. Am J Hypertens. 2002 Aug;15(8):735-8. [PubMed:12160198 ]
- Arakawa M, Murata Y, Rikimaru Y, Sasaki Y: Drug-induced isolated visceral angioneurotic edema. Intern Med. 2005 Sep;44(9):975-8. [PubMed:16258215 ]
- Donohoe JF, Kelly J, Laher MS, Doyle GD: Lisinopril in the treatment of hypertensive patients with renal impairment. Am J Med. 1988 Sep 23;85(3B):31-4. [PubMed:2844084 ]
- Donohoe JF, Laher M, Doyle GD, Long C, Glover DR, Cooper WD: Lisinopril treatment of hypertension in patients with impaired renal function. Gerontology. 1987;33 Suppl 1:36-41. [PubMed:2831115 ]
- Yuan AS, Gilbert JD: Time-resolved fluoroimmunoassay for the determination of lisinopril and enalaprilat in human serum. J Pharm Biomed Anal. 1996 May;14(7):773-81. [PubMed:8809701 ]
- Araujo MC, Melo RI, Del Nery E, Alves MF, Juliano MA, Casarini DE, Juliano L, Carmona AK: Internally quenched fluorogenic substrates for angiotensin I-converting enzyme. J Hypertens. 1999 May;17(5):665-72. [PubMed:10403610 ]
- Shionoiri H, Shigemasa T, Takasaki I: [Angiotensin-converting enzyme inhibitors: recent therapeutic aspect]. Nihon Rinsho. 1997 Aug;55(8):2067-74. [PubMed:9284425 ]
|
---|